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: sunxl_fmmu@16Abstract A sensitive and speciﬁc liquid-chromatography tandem mass spectrometry (LC-MS/MS)
assay has been developed and validated for the simultaneous quantiﬁcation of ivabradine and its active
metabolite N-desmethylivabradine in human plasma and urine. The assay employed a single liquid–liquid
extraction of the analytes from plasma and urine samples, and diazepam was used as internal standard
(IS). The chromatographic separation was achieved on a Diamonsil C18 column (150 mm 4.6 mm,
5 mm, Dikma) using a mixture of methanol and aqueous 5 mM ammonium acetate buffer containing
0.2% formic acid (80:20, v/v) as mobile phase. The assay for ivabradine and N-desmethylivabradine in
plasma showed good linearity (rZ0.99) over the ranges 0.1013–101.3 ng/mL and 0.085–25.5 ng/mL,
respectively. The assay for ivabradine and N-desmethylivabradine in urine showed good linearity
(rZ0.99) over the ranges 10.13–6078 ng/mL and 8.5–850 ng/mL, respectively. The intra- and inter-day
accuracy and precision values were found to be within the assay variability limits (RSDo15%) in
accordance with FDA guidelines. The methods were successfully used for evaluating the pharmaco-
kinetic properties of ivabradine and N-desmethylivabradine in human plasma and urine in Chinese
healthy volunteers.
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Chengtao Lu et al.2061. Introduction
Ivabradine (Fig. 1) is the ﬁrst representative of the new class of
exclusive heart rate-reducing agent and has been widely used
as a bradycardic agent, selectively inhibiting the If current in
the sinoatrial node1,2. Ivabradine protects myocardium in
acute ischemic conditions and has favorably sustained remo-
deling properties in the long term. The antianginal and anti-
ischemic efﬁcacy of ivabradine in patients with angina pectoric
have been demonstrated in controlled clinical trials3–7. Its
N-dealkylated metabolite has also been shown to decrease
heart rate in pre-clinical studies when administered to dogs8.
Therefore it was necessary to determine ivabradine and its
active metabolite N-desmethylivabradine for pharmacokinetic
evaluation.
As we all know, ivabradine is mainly metabolized by
cytochrome P450 (CYP) isoenzyme 3A4 in human liver.
Genetic variation in this isoenzyme has been surveyed in an
ethnically diverse population9–11. Researches about the dispo-
sition and metabolic fate of ivabradine have been carried out in
humans12–14. Comparison of the results of pharmacokinetic
studies was conducted in healthy white subjects living in Spain
and Romania14, suggesting that Cmax and AUC0N of ivab-
radine were 2-fold greater in Spanish than in Romanian when
administered 10 mg of ivabradine alone. Although ivabradine
has been approved to conduct clinical trial in China by SFDA,
little information is available on the pharmacokinetic proper-
ties of ivabradine in Chinese subjects. Therefore, it is urgent to
investigate the pharmacokinetic properties of ivabradine in
healthy Chinese people. In addition, it is reported12–14 that the
metabolic clearance of ivabradine accounts for about 80%, the
other 20% of clearrence corresponds to a renal clearance. No
pharmacokinetic study of ivabradine in human urine samples
has been reported yet.
Various methods have been reported for the determination
of ivabradine and N-desmethylivabradine in biological sam-
ples, which involved high-performance liquid chromatography
with ﬂuorescence detection15 and liquid chromatography-
tandem mass spectrometry (LC-MS/MS)16,17. Taking into
consideration of the low levels of ivabradine and N-desmethy-
livabradine in human blood and urine, LC-MS/MS method is
the ﬁrst choice for our determination purpose. The two
reported LC-MS/MS methods were limited by high cost
extraction procedure of automated solid-phase extraction
system. And there was also no LC-MS/MS method reportedFigure 1 Chemical structures of (A) Ivabradine,for determination of ivabradine and its metabolites in urine.
Our aim was to develop a simple, inexpensive, sensitive and
accurate LC-MS/MS method to determine ivabradine and
N-desmethylivabradine simultaneously in human plasma and
urine, and to study the pharmacokinetics of ivabradine and its
active metabolite in healthy Chinese volunteers.2. Materials and methods
2.1. Chemicals and reagents
Ivabradine hydrochloride tablets (2.5 mg per tablet) was
supplied by Changzhou Siyao Pharmaceutical group Co.,
Ltd. (Changzhou, China), as well as the reference substances
of ivabradine (purity499.0%) and N-desmethylivabradine
(purity499.0%). Diazepam (internal standard, IS) reference
standard (purity499.5%) was purchased from the National
Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China). HPLC-grade methanol was pur-
chased from Tedia Company Inc. (Fairﬁeld, USA). Formic
acid, ammonium acetate and ethyl acetate were all purchased
from Nanjing Chemical Reagent Factory (Nanjing, China).
Puriﬁed water obtained through Milli-Q system (Millipore,
USA) was used throughout the experiment.
2.2. Instrumentation
The LC-MS/MS system consisted of an Agilent 1200 series
HPLC and an Agilent 6410 triple quadrupole mass spectrometer
equipped with an electrospray ionization source (Agilent Tech-
nologies, USA). The chromatographic separation was performed
on a Diamonsil C18 column (150 mm 4.6 mm, 5 mm, Dikma)
column. All data were acquired employing Agilent 6410 quanti-
tative analysis version analyst data processing software.
2.3. Chromatographic and MS/MS condition
The mobile phase was a mixture of methanol and aqueous
ammonium acetate buffer (5 mM) containing 0.2% (v/v)
formic acid (80:20, v/v), which was pumped at a ﬂow rate of
0.6 mL/min and the total run time was 7.0 min. The chromato-
graphic separation was performed at 40 1C with a small injection
of 5.0 mL of plasma sample or 2.0 mL of urine sample.(B) N-desmethylivabradine and (C) Diazepam.
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scan mode was with the following settings: nebulizer pressure,
50 psi; drying gas temperature, 325 1C; dry gas ﬂow, 12 L/min;
dwell time per transition, 150 ms; resolution, unit. Analytes were
quantiﬁcated by multiple monitoring (MRM) employing the
following precursor to product ion transitions and parameters:
ivabradine 469.2-177.1 with fragmentor voltage (FV) 140 V and
collision energy (CE) 25 eV; N-desmethylivabradine 455.3-177.1
with FV 140 V and CE 23 eV; diazepam 285.1-193.1 with FV
150 V and CE 32 eV.
2.4. Stock and working solutions
The stock solutions of ivabradine (1.013 mg/mL), N-des-
methylivabradine (425 mg/mL) and the IS (1 mg/mL) were
separately prepared in methanol. Serial dilutions were pre-
pared with methanol–water (80:20, v/v) at concentrations
of 10.13 mg/mL, 1.013 mg/mL, 101.1 ng/mL and 10.13 ng/mL
for ivabradine and 8.5 mg/mL, 0.85 mg/mL, 85 ng/mL and
8.5 ng/mL for N-desmethylivabradine, respectively. Working
solutions of IS were prepared by further diluting the IS stock
solutions with methanol–water (80:20, v/v) at concentrations
of 20 and 2 mg/mL. All the working standard solutions were
stored at 5 1C.
2.5. Preparation of calibration curves and quality control
samples
Calibration standard and quality control (QC) plasma samples
were prepared by diluting corresponding standard solutions
with drug-free human plasma. Two analytes and IS were
spiked into human plasma to produce ﬁnal concentrations
0.1013–101.3 ng/mL for ivabradine and 0.085–25.5 ng/mL for
N-desmethylivabradine, respectivly. Slimilarly, two analytes
and IS were spiked into urine to produce ﬁnal concentrations
10.13–6078 ng/mL for ivabradine and 8.5–850 ng/mL for
N-desmethylivabradine, respectively. The suitability of the
calibration model was conﬁrmed by back-calculating the
concentration of the calibration standards.
The QC samples of three different concentration levels (0.203,
5.065, 75.975 ng/mL for ivabradine and 0.17, 2.55, 12.75 ng/mL
for N-desmethylivabradine in human plasma; 30.39, 303.9,
5065 ng/mL for ivabradine and 25.5, 255, 680 ng/mL for
N-desmethylivabradine in human urine) were selected to cover
the entire range of calibrations.
2.6. Sample preparation
For plasma sample preparation, a 1 mL of aliquot plasma sample
was mixed with 50 mL of IS working solution at 2 mg/mL. The
plasma mixture was extracted with 4 mL of ethyl acetate, vortex-
mixed for 3 min, and then centrifuged at 4000 rpm for 10 min.
The organic layer was removed and evaporated under a stream of
nitrogen gas in the thermostatically controlled water-bath main-
tained at 40 1C until completely dry. The residue was dissolved in
200 mL of mobile phase, vortex-mixed for 1 min, and centrifuged
at 16,000 rpm for 5 min. 5 mL of the supernatant was then
injected into the LC-MS/MS system for analysis.
For urine sample preparation, a 0.1 mL of aliquot urine sample
was mixed with 10 mL of IS working solution at 20 mg/mL. The
urine mixture was extracted with 2 mL of ethyl acetate, vortex-mixed for 3 min, and then centrifuged at 4000 rpm for 10 min.
The organic layer was removed and evaporated under a stream of
nitrogen gas in the thermostatically controlled water-bath main-
tained at 40 1C until completely dry. The residue was dissolved in
700 mL of mobile phase, vortex-mixed for 1 min, and centrifuged
at 16,000 rpm for 5 min. 2 mL of the supernatant was then injected
into the LC-MS/MS system for analysis.
2.7. Assay validation
2.7.1. Speciﬁcity
Speciﬁcity of the method was investigated by analyzing the
chromatograms of six different batches of blank human
plasma and urine, as well as the corresponding spiked samples.
Each blank sample was tested following the sample prepara-
tion procedures and under the chromatographic conditions
described above to ensure no interference from plasma
and urine.
2.7.2. Matrix effects
The matrix effects of each analyte were evaluated by compar-
ing the peak responses of analytes dissolved in extracts of
blank samples with those dissolved in mobile phase at the
same concentration as references. The criteria for acceptability
of the data are that the peak area ratios for the plasma or
urine extracts versus references are in the range of 85–115%.
2.7.3. Calibration curve, linearity, and lower limit of
quantiﬁcation
Calibration curves ranging from 0.1013 to 101.3 ng/mL for
ivabradine and 0.085 to 25.5 ng/mL for N-desmethylivabra-
dine in human plasma and ranging from 10.13 to 6078 for
ivabradine and 8.5 to 850 ng/mL for N-desmethylivabradine in
human urine were run on three separate days. The calibration
curves were constructed from the peak area ratios of each
analyte to IS versus analysts concentrations in plasma or urine
using a 1/C weighted linear least-squares regression model.
Coefﬁcients of correlation (r value) were required to beZ0.99.
The lower limit of quantiﬁcations (LLOQ) is deﬁned as the
lowest concentration of standard curve.
2.7.4. Accuracy, precision, and extraction recovery
The intra-day accuracy and precision were evaluated by
analyzing ﬁve replicates at three QC concentration levels for
human plasma and urine samples on the same day. The inter-
day assay accuracy and precision were determined by analyz-
ing the three-level QC samples on three runs in three
consecutive days.
The criteria for acceptability of the data included accuracy
within 715% deviation from the nominal values and a
precision of within 15% relative standard deviation (RSD),
except at the LLOQ, where it should not exceed 720%.
Extraction recoveries of ivabradine and N-desmethylivab-
radine were determined by comparing the two analytes
extracted from plasma and urine samples with standard
solutions without extraction at low, medium and high QC
concentrations, respectively.
2.7.5. Stability test
Stability experiments were performed under different condi-
tions to evaluate the analytes stability in plasma and urine
Chengtao Lu et al.208samples. The two analytes of low and high QC samples with
three determinations for each in blank plasma and urine were
processed on short-term storage conditions at room tempera-
ture 25 1C for 20 h, at least 90 days of long-term storage
(20 1C) and three freeze-thaw recycles.2.8. Pharmacokinetic study design
Ten healthy Chinese volunteers, including 5 males and 5
females were recruited to evaluate the pharmacokinetics of
ivabradine hydrochloride tablets. The informed consent state-
ments were signed by the volunteers and the protocol was
approved by the Committee on Human Rights Related to
Human Experimentation, Xijing Hospital. Ten volunteers
were each orally administered a single dose at 5 mg of
ivabradine hydrochloride tablets. Venous blood samples were
collected into heparinized tubes at 0 h (pre-dose) and 0.133,
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36 and 48 h post-dose,
and then centrifuged to obtain the plasma. Urine samples
were collected pre-dose and in the intervals of 0–2, 2–4,
4–6, 6–8, 8–10, 10–12, 12–16, 16–24 and 24–48 h post-dose.Figure 2 Mass spectra of the analytes. (A) full scan mass spectrum of
(C) full scan mass spectrum of IS; (D) product ion spectrum of [MþH]
of N-desmethylivabradine at m/z 177.1; (F) product ion spectrum ofThe volume of urine was recorded. The collected plasma and
urine samples were stored at 20 1C until analysis. QC samples
at three concentrations were assayed and distributed among
unknown samples in the analytical run.
The plasma and urine pharmacokinetic parameters after
oral administration of a single dose of ivabrandine tablet were
calculated by Drug and Statistics (DAS) software (version 2.0)
for Windows. All pharmacokinetic values were gained by the
non-compartmental model and expressed as mean7SD.3. Results and discussion
3.1. Selection of IS
It is necessary to select a proper IS to obtain high accuracy
when a mass spectrometer is used as detector. Diazepam was
chosen as the IS because of its similarity of retention time and
ionization with the analytes and the less endogenous inter-
ferences at m/z 177.1. The product ion mass spectra of
analytes and the IS are shown in Fig. 2.ivabradine; (B) full scan mass spectrum of N-desmethylivabradine;
þ of ivabradine at m/z 177.1; (E) product ion spectrum of [MþH]þ
[MþH]þ of IS at m/z 193.1.
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To optimize chromatographic conditions and obtain shorter
run time, different methanol ratios had been tried, and 80%
methanol was suitable for determination of the analysts. The
retention time of diazepam was sensitive to the concentration
of ammonium acetate and formic acid. A higher concentration
of ammonium acetate and formic acid led to a longer run time.
The mixture of methanol and 5 mM of aqueous ammonium
acetate buffer containing 0.2% formic acid (80:20, v/v) was
ﬁnally used as mobile phase. A ﬂow rate of 0.6 mL/min
permitted a run time of 7 min.3.3. Method validation
3.3.1. Selectivity
Selectivity was assessed by screening six different batches of
blank plasma. Fig. 3 shows the typical chromatograms of
drug-free plasma and urine, drug-free plasma and urine spiked
with analytes and IS. The retention time of the ivabradine,Figure 3 Representative chromatograms for ivabradine, N-desmethyli
blank urine sample (B), blank plasma spiked with 0.1013 ng/mL ivab
spiked with 10.13 ng/mL ivabradine and 8.5 ng/mL N-desmethylivabrN-desmethylivabradine, and IS were 2.53, 2.53, and 5.23 min
in plasma sample, 2.47, 2.48, and 5.32 min in urine sample,
respectively. No signiﬁcant peaks were observed in any of the
blank plasma and urine samples for the two analytes and IS.3.3.2. Linearity of calibration curves and lower limits of
quantiﬁcation
The calibration curves for ivabradine and N-desmethylivabradine
were assessed over the ranges of 0.1013–101.3 ng/mL and
0.085–25.5 ng/mL in human plasma, and 10.13–6078 ng/mL
and 8.5–850 ng/mL in human urine, respectively by least-squares
regression analysis. The calibration curve equation was Y¼
aXþb, where Y represented peak area ratios of analytes to IS
and X represented the analyte concentration. The typical calibra-
tion curve equations obtained were Y1¼0.0001796þ0.04518X
(r¼0.999), Y2¼0.001618þ0.01666X (r¼0.999) for ivabradine and
N-desmethylivabradine in human plasma, and Y3¼0.002634þ
0.0008504X (r¼0.999), Y4¼0.001026þ0.0004107X (r¼0.999)
for ivabradine and N-desmethylivabradine in human urine,
respectively.vabradine and IS from a drug-free blank plasma sample (A) and a
radine and 0.085 ng/mL N-desmethylivabradine (C), blank urine
adine(D).
Chengtao Lu et al.210The LLOQ of 0.1013 ng/mL and 0.085 ng/mL for ivabra-
dine and N-desmethylivabradine in plasma and the LLOQ of
10.13 ng/mL and 8.5 ng/mL for ivabradine and N-desmethy-
livabradine in urine were with the RSD and bias within720%.3.3.3. Matrix effects
Matrix interferences caused by plasma and urine endogenous
materials were evaluated by comparing the peak areas of the
post-spiked standards with those of the neat standard at the
QC concentrations. In this study, the peak area ratios of the
analytes in plasma were: ivabrandine 90.574.2%, 89.775.2%
and 92.678.9% at the concentrations of 0.2026, 5.065
and 75.975 ng/mL, respectively; N-desmethylivabradine 92.47
5.7%, 93.678.6% and 94.877.4% at the concentrations of
0.17, 2.55 and 12.75 ng/mL, respectively; the peak area ratios
of analytes in urine were: ivabrandine 90.173.6%, 88.976.8%
and 86.877.2% at the concentrations of 30.39, 303.9 and
5065 ng/mL, respectively; N-desmethylivabradine 87.475.2%,
91.276.4% and 85.778.2% at the concentrations of 25.5, 255
and 680 ng/mL, respectively. There was no matrics effect of
other substances on the ivabrandine and N-desmethylivabra-
dine detection in plasma or urine.3.3.4. Extraction recovery
Good extraction recoveries were found for both analytes.
Mean values of extraction recovery for ivabradine and
N-desmethylivabradine in human plasma and urine were all
above 75.7%.3.3.5. Precision and accuracy
Three concentrations of QC samples were analyzed to deter-
mine the accuracy and precision of the assay. Precision and
accuracy data for intra- and inter-day plasma and urine
samples were presented in Table 1. The accuracy expressed
as bias and precision expressed as RSD were all found to be
within the criteria limit.Table 1 Precision and accuracy for analysis of ivabradine and N
ﬁvereplicates per day).
Concentration
added (ng/mL)
Intra-run
Measured
concentration
7SD (ng/mL)
RS
Plasma
Ivabradine 0.2026 0.20770.0102 4.9
5.065 5.0870.171 3.4
75.975 82.972.90 3.5
N-desmethyl
ivabradine
0.17 0.18170.0123 6.8
2.55 2.8170.0962 3.4
12.75 12.671.53 1.2
Urine
Ivabradine 30.39 29.472.01 6.8
303.9 28279.36 3.4
5056 51857149 2.9
N-desmethyl
ivabradine
25.5 25.171.72 6.8
255 23477.98 3.4
680 69072.1 2.13.3.6. Stability
QC samples were subjected to short-term room temperature
conditions, long-term storage conditions (20 1C), and three
freeze-thaw recycles. All the stability studies were conducted at
two concentration levels with three determinations for each.
The stability experiment conﬁrmed that plasma and urine
samples were stable over 90 days when stored at 20 1C and
through 3 freeze-thaw cycles. The prepared plasma samples
were stable for at least 20 h at 25 1C (Table 2).3.4. Pharmacokinetic application
The sensitive and speciﬁc LC-MS/MS method was successfully
used for accurately characterizing the pharmacokinetics of
ivabradine and N-desmethylivabradine in human plasma and
urine. Proﬁles of the mean plasma concentration-time for
ivabradine and N-desmethylivabradine after a single oral dose
of 5 mg ivabradine hydrochloride tablets are shown in Fig. 4.
The proﬁles of urinary acuumulative excretion rate vs. time for
ivabradine and N-desmethylivabradine are presented in Fig. 5.
The main pharmacokinetic parameters of plasma and urine are
listed in Tables 3 and 4. The pharmacokinetics results showed
that plasma Cmax values of ivabradine and N-desmethylivab-
radine were 35.9878.68 ng/mL and 3.1171.61 ng/mL, and
T1/2 were 5.0371.19 h and 9.6471.32 h. The mean cumulative
urinary excretion rates of ivabradine and N-desmethylivabradine
up to 48 h were 14.074.65% and 2.0270.44%. Moreover, it
was the ﬁrst time to provide the pharmacokinetic properties of
ivabradine and N-desmethylivabradine in urine samples in
healthy volunteers.
Based on mean AUC and Cmax, ivabradine hydrochloride
tablets present the enhanced extent and rate absorption in
healthy Chinese subjects than in healthy Spain and Romania
subjects, which maybe result from the genetic variation of
cytochrome P450 (CYP) isoenzyme 3A4 in human liver and
need further research. The average Tmax and T1/2 visually did
not show signiﬁcant difference between ethnics. Considering-desmethylivabradine in human plasma and urine (n¼3 days,
Inter-run
D (%) Bias (%) Measured
concentration
7SD (ng/mL)
RSD (%) Bias
(%)
2.06 0.21070.0102 4.85 3.63
0.320 5.4370.298 5.49 7.17
9.31 72.777.75 10.7 4.32
6.55 0.18370.00783 2.37 7.38
10.32 2.6270.179 6.83 2.81
0.123 12.771.22 9.61 0.326
0.049 29.871.82 6.1 0.037
0.090 28175.89 2.1 0.093
0.006 52167162 3.1 0.012
0.014 24.671.41 5.7 0.037
0.081 23275.76 2.5 0.091
0.016 685721.1 3.1 0.007
Table 2 The stability of ivabradine and N-desmethylivabradine in human plasma and urine under different conditions (n¼3).
Ivabradine N-desmethylivabradine
Concentration
added (ng/mL)
Measured
concentration
7SD (ng/mL)
Bias (%) Concentration
added (ng/mL)
Measured
concentration
7SD (ng/mL)
Bias (%)
Plasma
Long-term 0.2026 0.21570.00567 6.35 0.170 0.19170.00451 12.2
75.975 82.671.38 8.75 12.7 13.170.613 2.36
Short-term 0.2026 0.22870.00512 12.4 0.170 0.15770.0142 7.45
75.975 70.771.94 6.97 12.7 13.070.300 1.92
Freeze-thaw 0.2026 0.19670.00490 3.47 0.170 0.15370.00252 10.2
75.975 74.777.06 1.69 12.7 13.070.0534 2.30
Urine
Long-term 30.39 27.270.683 12.2 25.5 22.470.392 12
5065 53757130 4.3 680 725713.2 6.6
Short-term 30.39 28.871.76 7 25.5 24.571.47 4.1
5065 54057231 4.9 680 721722.0 6
Freeze-thaw 30.39 29.171.34 6 25.5 22.670.383 11.3
5065 51537207 0.02 680 660725.1 2.8
Figure 4 Mean plasma concentration-time proﬁles of (A) ivabra-
dine and (B) N-desmethylivabradine after a single oral dose of 5 mg
ivabradine hydrochloride tablets. Data are expressed as mean7SD.
Figure 5 Total urinary excretion rate-time curve of (A) ivabra-
dine and (B) N-desmethylivabradine after a single oral dose of
5 mg ivabradine hydrochloride tablet.
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small, the pharmacokinetic results will need further research
with a larger sample size. However, to the best of our
knowledge this is the ﬁrst clinical study to investigate phar-
macokinetic properties of ivabradine hydrochloride tablets in
Chinese health volunteers. The results will add important
information to the clinical study of ivabradine hydrochloride
tablet in Chinese subjects.4. Conclusions
A simple, speciﬁc, rapid and inexpensive LC-MS/MS method
for analysis of ivabradine and N-desmethylivabradine in human
plasma and urine simultaneously has been developed and
validated for the ﬁrst time. Simple liquid–liquid extraction
Table 3 Pharmacokinetic parameters of ivabradine and
N-desmethylivabradine in plasma following a single oral dose
of 5 mg ivabradine hydrochloride tablets (Mean7SD, n¼10).
Parameter Single dose (5 mg)
Ivabradine N-desmethylivabradine
Cmax, ng/mL 35.9878.68 3.1171.61
AUC0t,
ng/mL/h
169.60733.09 23.3379.17
AUC0N,
ng/mL/h
171.19733.45 25.3979.49
Tmax, h 1.1570.24 1.3070.26
T1/2, h 5.0371.19 9.6471.32
CL, L/h 30.2375.86 238.767131.34
Table 4 Pharmacokinetic parameters of ivabradine and
N-desmethylivabradine in urine following a single oral dose of
5 mg ivabradine hydrochloride tablets (Mean7SD, n¼10).
Parameter Single dose (5 mg)
Ivabradine N-desmethylivabradine
T1/2, h 5.5870.601 12.473.19
Ke, 1/h 0.12570.013 0.05970.015
Total urinary
excretion
amount (mg)
7017233 101722
Total urinary
excretion
rate (%)
14.074.65 2.0270.44
Chengtao Lu et al.212sample preparation procedure and chromatography analysis
were used in the method. Although LC-MS/MS method have
been reported for the determination of ivabradine and
N-desmethylivabradine in biological samples, which employed
a high cost extraction procedure of automated solid-phase
extraction system. Our method was low-cost, simple and sensitive
comparatively compared with the reported method. The method
has been successfully applied to the determination of the
ivabradine and N-desmethylivabradine levels in plasma and
urine after a single oral administration of a 5-mg ivabradine
hydrochloride tablet. The sensitive and speciﬁc method was
suitable for analysis of the large batches of sample.
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